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Sirs,
We thank Drs. von Schnakenburg and Krger for their
comments. They rightfully raise the question of the safety
of sodium nitroprusside administration in newborn pa-
tients and ask for details of our recently reported patient
[1]. The newborn child received sodium nitroprusside for
6 days, at a maximum dosage of 4 mg/kg per min for 48 h,
after she failed to respond to several boluses of intrave-
nous hydralazine. The thiocyanate level, measured after
48 h of infusion, was normal at 8 mg/ml (toxic levels
>30 mg/ml). Regularly repeated blood analysis never
showed lactic acidosis or methemoglobinemia. The child
had invasive blood pressure measurement during the en-
tire period of sodium nitroprusside infusion. Blood pres-
sure responded well to that therapy, without any hypo-
tensive episodes.
In addition to its potent vasoactive properties, sodium
nitroprusside possesses unique toxicities that Dr. von
Schnakenburg et al. allude to in their comments. Sodium
nitroprusside is rapidly transformed into nitric oxide
(NO) and cyanate (CN). CN is then metabolized/elimi-
nated via three routes: (1) an irreversible transformation
into thiocyanate (detoxification), (2) a binding to hy-
droxycobalamin, to form cyancobalamin (which is elimi-
nated via the kidney), and (3) intracellular metabolism by
oxidase, which can lead to cellular asphyxia and lactic
acidosis. Methemoglobinemia can also occur [2, 3, 4].
Therefore, sodium nitroprusside administration is not
devoid of side effects, although they are deemed to be
rare, and often associated with particular pathological
conditions (renal failure, malnutrition, hepatic failure,
smoking) that can predict their occurrence [2, 3, 5, 6].
Our child clearly did not show any side effects of sodium
nitroprusside administration.
Emergency treatment of hypertension in the neonate
remains difficult, with currently very few tested drugs
available. Indeed, sodium nitroprusside has been rec-
ommended in the acute treatment of hypertensive emer-
gencies, or in patients with refractory congestive heart
failure [7, 8, 9, 10], with the recommendation of regu-
larly checking blood gas (for the presence of methe-
moglobinemia and metabolic acidosis), and plasma levels
of thiocyanate and lactate. Calcium channel blockers or
beta-adrenoreceptor antagonists have been used suc-
cessfully in the newborn to treat hypertension or various
arrhythmias [11], although their use has also been asso-
ciated with cardiovascular collapse, especially in the
newborn [12, 13]. The cardiodepressant adverse effect of
calcium channel blockers or beta-adrenoreceptor antag-
onists is especially pronounced in patients with pre-ex-
isting left ventricular impairment [14], as in our patient.
We felt that both calcium channel blockers and beta-
adrenoreceptor antagonists were contraindicated in our
patient with severely depressed myocardial function.
In summary, in cases of hypertensive emergency with
heart failure, sodium nitroprusside is probably a better
alternative than continuous administration of calcium
channel blockers and beta-adrenoreceptor antagonists,
and is clearly superior to intermittent administration of
antihypertensive drugs. In our experience, the use of
sodium nitroprusside by incremental infusion in the
critical early phase of management has resulted in im-
proved control of hypertension without any sudden hy-
potensive episodes seen when bolus injections are used.
Nevertheless, the comments of Dr. von Schnakenburg are
welcomed: moderate to high doses (>3 mg/kg per min) of
sodium nitroprusside, given for >72–96 h, are associated
with significant side effects, which are potentially lethal.
Children given sodium nitroprusside should be careful-
ly followed with invasive blood pressure and regular
blood gases, lactate, and thiocyanate measurements. So-
dium nitroprusside administration should be decreased or
stopped as soon as possible. Co-administration of thio-
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sulfate with sodium nitroprusside to prevent cyanide
toxicity has been shown to be successful, but is not yet
common practice [15].
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